Get Our Free Research Email
Conference Calendar 
May 20-23 - Current Concepts in Joint Replacement Spring 2012
May 23-25 - 13th EFORT Congress 2012
Complete Calendar »
|
Orthopedic and Dental Industry News
November 2006
We'd like to remind you that our Allograft teleseminar with our Research team and Jeff Sandler, an industry veteran, next week. Jeff will discuss the allograft industry, current issues and his advice for selecting a tissue bank. Report purchasers will... more
Earnings ORTHOsoft reported 3Q:06 revenues of CAN $3.8 million (US $3.3 million), up 59% from CAN $2.4 million (US $2.1 million) in 3Q:05. ORTHOsoft manufactures computer aided orthopedic surgery devices, and they attribute the 3Q:06 growth to increased navigation systems... more
In 2005, Nature reported that companies were "queuing up" to conduct clinical trials in China, where a large population simplifies the enrollment process and research could be conducted at lower cost than in the U.S. Similar trends can be seen... more
Earlier this month, the Office of the Inspector General (OIG) issued a new opinion over gainsharing. The cardiologist group who submitted the request received a favorable response, with the OIG determining that though the arrangement may violate the Social Seucrity... more
Delta Dental of Michigan, Ohio and Indiana has announced it will offer coverage of dental implants as a part of its standard coverage package, beginning January 1, 2007. Specifically, patients will be able to choose between receiving a bridge or... more
The first arm of the Spine Patients Outcome Research Trial ("SPORT") study was released by the Journal of the American Medical Association yesterday. The $13.5 million NIH funded SPORT study has been designed to determine the efficacy of spine surgery... more
For 2Q:07, Medtronic reported overall revenue of $3.08 billion, which represented year over year growth of 11% (10% on a constant currency basis), beating analyst estimates of $2.97 billion. During the quarter spinal instrumentation generated revenues of $421 million, an... more
Zimmer announced this morning that Ray Elliott is planning a 1H:07 retirement from his role as President and Chief Executive Officer. The Company also added that Mr. Elliott will remain as Chairman for at least one year from today. Elliott... more
This morning Orthovita announced that it hopes to do a 7.7 million share offering at $3.25 a share in order to raise approximately $23 million net of fees. At least $9 million of the proceeds is expected to be used... more
Earnings: Langer reported their 3Q:06 results on Tuesday, which included a net loss of approximately $553,000, or $.06 per share on a fully diluted basis. Compared to 3Q:05, there was a net income $236,000, or $.02 per share on a... more
There is a pattern worth recognizing in the orthopedics industry - companies are taking drugs already on the market and exploring new indications, specifically for orthopedic related applications. From a safety perspective, this model makes a lot of sense -... more
Furthering the trend of the interoperability of medical devices (emphasized at last week's MDMA meeting) is a pilot program headed by Massachusetts General Hospital and the Center for Integration of Medicine and Innovative Technology. The program features the use of... more
With the Democrats taking over the House and Senate, new healthcare priorities are bound to emerge: an early target is pharma, specifically regarding legislation that would allow the government to negotiate directly with drug companies over prices as well as... more
Last week we attended the 9th Annual MDMA Coverage Reimbursement and Health Policy Conference in Washington D.C. As we've previously discussed, the MDMA events are a terrific opportunity for small- to medium-sized device companies to network, provide insight on topical... more
Medtronic, Inc. announced yesterday that the FDA Dental Products Advisory Panel had unanimously voted to recommend approval of INFUSE Bone Graft for certain oral and maxillofacial procedures. If the FDA agrees with that panel's recommendation, the US indications for INFUSE... more
Earnings: Tissue Grafting: Regeneration Technologies, Inc. announced revenues of $18.1 million for 3Q:06, compared to $22.5 million for 3Q:05. RTI said the decrease in revenues was due to fewer tissues available for processing demand and reduced orders from primary distributors.... more
This week we attended the Cleveland Clinic Medical Innovation Summit where industry luminaries gathered to discuss the future of medicine. The predominant themes were economics and advanced neurosciences. Notably, the ultimate form of evidence based medicine was highlighted: an elated... more
GEM OS1 is BioMimetic Therapeutics' developmental product for open fracture reduction or fractures requiring surgery in orthopedic applications. The therapy consists of both particulate Beta-tricalcium phosphate (β-TCP) with recombinant human Platelet-Derived Growth Factor (rhPDGF-ββ). BioMimetic has a similar, already-marketed product,... more
February 2010 update: This report is no longer available for purchase. Learn more here. Even though processor scandals have tainted the allograft business, human bone graft isn't going away anytime soon. It's too important to spinal fusion and many other... more
February 2010 update: This report is no longer available for purchase. Learn more here. This is a sample chapter from our new research report on Allograft. Learn more about the report here, and purchase and download it for $279 from... more
Earnings Biologics: Orthovita reported 3Q:06 product sales came in at $11 million, up 32% compared to 3Q:05. Net loss for the quarter was $3.7 million, or a loss of $0.07 per share. The Company beat analysts' EPS estimates by $0.02,... more
With limitations of time and money, designing a "perfect" medical device may be an unattainable goal. Practical limitations prompt designers stop at adequate designs lacking forseeable flaws - but new technology can give designers more freedom to test and develop... more
This morning Smith & Nephew issued a statement confirming speculations that it has been speaking with Biomet. The Company stated that it, "it has held very preliminary talks with the US medical devices company, Biomet Inc. No agreement has been... more
U.S. devicemakers face challenges in designing clinical trials, among them low recruitment rates and high costs. India may have the answer. Among the benefits, Pacific Bridge Medical reports in their November 2006 newsletter that cost savings can reach 40 to... more
Complete Archive
|
